Search Results - "Cancer immunology research"

Myeloid-Derived Suppressor Cells by Gabrilovich, Dmitry I

“…Myeloid cells developed evolutionarily as a major mechanism to protect the host. They evolved as a critical barrier against infections and are important…”
Get more information

IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype by Alizadeh, Darya, Wong, Robyn A, Yang, Xin, Wang, Dongrui, Pecoraro, Joseph R, Kuo, Cheng-Fu, Aguilar, Brenda, Qi, Yue, Ann, David K, Starr, Renate, Urak, Ryan, Wang, Xiuli, Forman, Stephen J, Brown, Christine E

“…Improvements in the quality and fitness of chimeric antigen receptor (CAR)-engineered T cells, through CAR design or manufacturing optimizations, could enhance…”
Get more information

T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection by Trujillo, Jonathan A, Sweis, Randy F, Bao, Riyue, Luke, Jason J

“…Immunotherapies such as checkpoint-blocking antibodies and adoptive cell transfer are emerging as treatments for a growing number of cancers. Despite clinical…”
Get more information

Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer by Zhao, Sha, Ren, Shengxiang, Jiang, Tao, Zhu, Bo, Li, Xuefei, Zhao, Chao, Jia, Yijun, Shi, Jinpeng, Zhang, Limin, Liu, Xiaozhen, Qiao, Meng, Chen, Xiaoxia, Su, Chunxia, Yu, Hui, Zhou, Caicun, Zhang, Jun, Camidge, D Ross, Hirsch, Fred R

“…The lack of response to treatment in most lung cancer patients suggests the value of broadening the benefit of anti-PD-1/PD-L1 monotherapy. Judicious dosing of…”
Get more information

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC by Tumeh, Paul C, Hellmann, Matthew D, Hamid, Omid, Tsai, Katy K, Loo, Kimberly L, Gubens, Matthew A, Rosenblum, Michael, Harview, Christina L, Taube, Janis M, Handley, Nathan, Khurana, Neharika, Nosrati, Adi, Krummel, Matthew F, Tucker, Andrew, Sosa, Eduardo V, Sanchez, Phillip J, Banayan, Nooriel, Osorio, Juan C, Nguyen-Kim, Dan L, Chang, Jeremy, Shintaku, I Peter, Boasberg, Peter D, Taylor, Emma J, Munster, Pamela N, Algazi, Alain P, Chmielowski, Bartosz, Dummer, Reinhard, Grogan, Tristan R, Elashoff, David, Hwang, Jimmy, Goldinger, Simone M, Garon, Edward B, Pierce, Robert H, Daud, Adil

“…We explored the association between liver metastases, tumor CD8 T-cell count, and response in patients with melanoma or lung cancer treated with the anti-PD-1…”
Get more information

Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer by Tchou, Julia, Zhao, Yangbing, Levine, Bruce L, Zhang, Paul J, Davis, Megan M, Melenhorst, Jan Joseph, Kulikovskaya, Irina, Brennan, Andrea L, Liu, Xiaojun, Lacey, Simon F, Posey, Jr, Avery D, Williams, Austin D, So, Alycia, Conejo-Garcia, Jose R, Plesa, Gabriela, Young, Regina M, McGettigan, Shannon, Campbell, Jean, Pierce, Robert H, Matro, Jennifer M, DeMichele, Angela M, Clark, Amy S, Cooper, Laurence J, Schuchter, Lynn M, Vonderheide, Robert H, June, Carl H

“…Chimeric antigen receptors (CAR) are synthetic molecules that provide new specificities to T cells. Although successful in treatment of hematologic…”
Get more information

Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC by Santini, Fernando C, Rizvi, Hira, Plodkowski, Andrew J, Ni, Andy, Lacouture, Mario E, Gambarin-Gelwan, Maya, Wilkins, Olivia, Panora, Elizabeth, Halpenny, Darragh F, Long, Niamh M, Kris, Mark G, Rudin, Charles M, Chaft, Jamie E, Hellmann, Matthew D

“…Considering retreatment following recovery from an immune-related adverse event (irAE) is a common clinical scenario, but the safety and benefit of retreatment…”
Get more information

Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs by Diamond, Julie M, Vanpouille-Box, Claire, Spada, Sheila, Rudqvist, Nils-Petter, Chapman, Jessica R, Ueberheide, Beatrix M, Pilones, Karsten A, Sarfraz, Yasmeen, Formenti, Silvia C, Demaria, Sandra

“…Radiotherapy (RT) used at immunogenic doses leads to accumulation of cytosolic double-stranded DNA (dsDNA) in cancer cells, which activates type I IFN (IFN-I)…”
Get more information

Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade by Budimir, Natalija, Thomas, Graham D, Dolina, Joseph S, Salek-Ardakani, Shahram

“…Anti-PD-1/PD-L1 immune checkpoint blockade (ICB) therapy has revolutionized the treatment of many types of cancer over the past decade. The initial therapeutic…”
Get more information

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma by Baumeister, Susanne H, Murad, Joana, Werner, Lillian, Daley, Heather, Trebeden-Negre, Helene, Gicobi, Joanina K, Schmucker, Adam, Reder, Jake, Sentman, Charles L, Gilham, David E, Lehmann, Frédéric F, Galinsky, Ilene, DiPietro, Heidi, Cummings, Kristen, Munshi, Nikhil C, Stone, Richard M, Neuberg, Donna S, Soiffer, Robert, Dranoff, Glenn, Ritz, Jerome, Nikiforow, Sarah

“…NKG2D ligands are widely expressed in solid and hematologic malignancies but absent or poorly expressed on healthy tissues. We conducted a phase I…”
Get more information

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade by Johnson, Douglas B, Frampton, Garrett M, Rioth, Matthew J, Yusko, Erik, Xu, Yaomin, Guo, Xingyi, Ennis, Riley C, Fabrizio, David, Chalmers, Zachary R, Greenbowe, Joel, Ali, Siraj M, Balasubramanian, Sohail, Sun, James X, He, Yuting, Frederick, Dennie T, Puzanov, Igor, Balko, Justin M, Cates, Justin M, Ross, Jeffrey S, Sanders, Catherine, Robins, Harlan, Shyr, Yu, Miller, Vincent A, Stephens, Philip J, Sullivan, Ryan J, Sosman, Jeffrey A, Lovly, Christine M

“…Therapeutic antibodies blocking programmed death-1 and its ligand (PD-1/PD-L1) induce durable responses in a substantial fraction of melanoma patients. We…”
Get more information

Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia by Scharping, Nicole E, Menk, Ashley V, Whetstone, Ryan D, Zeng, Xue, Delgoffe, Greg M

“…Blockade of the coinhibitory checkpoint molecule PD-1 has emerged as an effective treatment for many cancers, resulting in remarkable responses. However,…”
Get more information

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells by Zah, Eugenia, Lin, Meng-Yin, Silva-Benedict, Anne, Jensen, Michael C, Chen, Yvonne Y

“…The adoptive transfer of T cells expressing anti-CD19 chimeric antigen receptors (CARs) has shown remarkable curative potential against advanced B-cell…”
Get more information

RIPK3 Orchestrates Fatty Acid Metabolism in Tumor-Associated Macrophages and Hepatocarcinogenesis by Wu, Lei, Zhang, Xiao, Zheng, Lu, Zhao, Huakan, Yan, Guifang, Zhang, Qi, Zhou, Yu, Lei, Juan, Zhang, Jiangang, Wang, Jingchun, Xin, Rong, Jiang, Lu, Peng, Jin, Chen, Qian, Lam, Sin Man, Shui, Guanghou, Miao, Hongming, Li, Yongsheng

“…Metabolic reprogramming is critical for the polarization and function of tumor-associated macrophages (TAM) and hepatocarcinogenesis, but how this…”
Get more information

A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients by Cursons, Joseph, Souza-Fonseca-Guimaraes, Fernando, Foroutan, Momeneh, Anderson, Ashley, Hollande, Frédéric, Hediyeh-Zadeh, Soroor, Behren, Andreas, Huntington, Nicholas D, Davis, Melissa J

“…Natural killer (NK) cell activity is essential for initiating antitumor responses and may be linked to immunotherapy success. NK cells and other innate immune…”
Get more information

The interplay of immunotherapy and chemotherapy: harnessing potential synergies by Emens, Leisha A, Middleton, Gary

“…Although cancer chemotherapy has historically been considered immune suppressive, it is now accepted that certain chemotherapies can augment tumor immunity…”
Get more information

NF-κB, an active player in human cancers by Xia, Yifeng, Shen, Shen, Verma, Inder M

“…NF-κB comprises a family of five transcription factors that form distinct protein complexes, which bind to consensus DNA sequences at promoter regions of…”
Get more information

Lactate-Mediated Acidification of Tumor Microenvironment Induces Apoptosis of Liver-Resident NK Cells in Colorectal Liver Metastasis by Harmon, Cathal, Robinson, Mark W, Hand, Fiona, Almuaili, Dalal, Mentor, Keno, Houlihan, Diarmaid D, Hoti, Emir, Lynch, Lydia, Geoghegan, Justin, O'Farrelly, Cliona

“…Colorectal cancer is the third most common malignancy worldwide, with 1.3 million new cases annually. Metastasis to the liver is a leading cause of mortality…”
Get more information

PD-L1 expression in triple-negative breast cancer by Mittendorf, Elizabeth A, Philips, Anne V, Meric-Bernstam, Funda, Qiao, Na, Wu, Yun, Harrington, Susan, Su, Xiaoping, Wang, Ying, Gonzalez-Angulo, Ana M, Akcakanat, Argun, Chawla, Akhil, Curran, Michael, Hwu, Patrick, Sharma, Padmanee, Litton, Jennifer K, Molldrem, Jeffrey J, Alatrash, Gheath

“…Early-phase trials targeting the T-cell inhibitory molecule programmed cell death ligand 1 (PD-L1) have shown clinical efficacy in cancer. This study was…”
Get more information

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade by Zhou, Jun, Mahoney, Kathleen M, Giobbie-Hurder, Anita, Zhao, Fengmin, Lee, Sandra, Liao, Xiaoyun, Rodig, Scott, Li, Jingjing, Wu, Xinqi, Butterfield, Lisa H, Piesche, Matthias, Manos, Michael P, Eastman, Lauren M, Dranoff, Glenn, Freeman, Gordon J, Hodi, F Stephen

“…Blockade of the pathway including programmed death-ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) has produced clinical benefits in…”
Get more information